Using urine tests to reduce checkups for bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether monitoring urine tumor DNA can safely reduce how often patients need invasive cystoscopy checkups after initial treatment for non-muscle invasive bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk non-muscle invasive bladder cancer (defined by urology guidelines).
- You completed induction therapy with BCG or gemcitabine/docetaxel.
- Your first checkup after induction therapy showed no cancer (negative cytology and cystoscopy, with or without biopsy).
- You did not have high-risk bladder cancer in the last 3 years.
- You did not receive prior induction intravesical therapy for a previous high-risk cancer.
- You do not have variant histology or cancer in the upper urinary tract.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approaches for people with early-stage bladder cancer that has a low chance of coming back: either careful monitoring without immediate treatment, or receiving chemotherapy directly into the bladder to lower the risk of recurrence. It aims to see if monitoring alone is as good as chemotherapy for those with a low risk detected by a urine test.
This trial tests a new ablation therapy (a treatment that destroys tumors without surgery) in people with low-grade, non-invasive bladder cancer that comes back. It aims to see if this therapy can help avoid repeated surgeries.
This study tests a new drug called UGN-501, given directly into the bladder through a catheter, for people whose bladder cancer (non-muscle invasive) has returned after previous treatments. It aims to find the right dose and see if it helps control the cancer.
This Phase 2 study tests whether urine tests can help monitor “non-muscle-invasive” bladder cancer without doing as many invasive bladder scopes (cystoscopies). If you qualify, you may be able to replace some scope visits with urine sample testing while still keeping close watch for cancer coming back.
This trial tests non-invasive tests (using urine samples and scheduled bladder procedures) to help detect bladder cancer. It may be helpful if you are having bladder evaluation or surgery and your care team wants better ways to detect cancer without invasive testing beyond what you already need.
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
Hear when a new Non-muscle Invasive Bladder Cancer (NMIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.